Overview

Surgical procedures are typically performed to improve health or as a life-saving intervention. However, their benefits may sometimes be offset by postoperative complications. One such complication is pouchitis, an inflammatory condition that commonly occurs after ileal pouch-anal anastomosis (IPAA) surgery, which is performed to treat ulcerative colitis.¹ 

Fortunately, this condition can often be managed effectively with first-line antibiotics, such as Ciprofloxacin and Metronidazole. These antibiotics have proven effective in treating cases of pouchitis. However, like most treatment options, they also carry potential drawbacks, including side effects, reduced effectiveness in certain cases and the risk of antibiotic resistance development.

This article explores pouchitis and examines the role of the antibiotics Ciprofloxacin and Metronidazole in its treatment.

What is pouchitis?

Pouchitis is an inflammatory condition that commonly arises as a complication in patients who have undergone IPAA surgery. It occurs within the pouch that is surgically constructed during the procedure.¹^,² Pouchitis is relatively common, affecting up to 45% of patients following IPAA surgery.³ 

The severity of pouchitis is typically determined using the Pouchitis Disease Activity Index (PDAI), an 18-point scoring system based on clinical symptoms, endoscopic findings, and histological analysis.

Pouchitis is generally classified into two types:

• Acute pouchitis: Symptoms last for 4 weeks or less and the PDAI score is 7 or higher
• Chronic pouchitis: Symptoms last for 4 or more weeks and the PDAI score is 6 or lower³^,⁴

Causes and risk factors of pouchitis

Causes

Pouchitis is believed to be caused by an imbalance of gut bacteria within the ileal pouch, triggering an immune response. During IPAA surgery, a part of the small intestine is fashioned into a pouch and connected to the annus, thereby exposing it to a new population of colonic-type bacteria. These bacteria may compete with the preexisting types in the small intestine. If the introduced bacteria are pathogenic, they can provoke inflammation through immune system activation.² 

The primary bacterial species believed to cause pouchitis include Clostridium perfringens and hemolytic strains of Escherichia coli.⁴

Risk factors 

Some of the risk factors that may contribute to the onset of pouchitis are:

• Underlying inflammatory bowel disease (IBD) - linked to a higher risk of pouchitis
• Use of nonsteroidal anti-inflammatory drugs (NSAIDs) - e.g. ibuprofen may lead to the onset of pouchitis
• Pelvic radiation therapy - Higher risk of pouchitis when radiation involves the pelvic area³
• Genetic mutations - Certain genetic predispositions may contribute
• Extensive colitis - A more severe form of colitis may increase susceptibility¹ 

Symptoms and diagnosis of pouchitis

Symptoms

• Diarrhoea
• Stomach/joint pain
• Cramps
• Fever
• Frequent excretion of stool
• Bowel incontinence²
• Blood present in stool 
• Loose stool¹
• Chills³

Diagnosis

The first step for the diagnosis of pouchitis is to check the symptoms and medical history. This is followed by the insertion of an endoscope into the pouch to look for any potential inflammation. In some cases, the endoscope may be also used to take a tissue sample (biopsy) to conduct further tests to rule out other causes.

Other additional diagnostic tools may include:

• Contrast pouchography - An X-ray study in which a dye is injected into the pouch to make it visible
• Computed tomography (CT) scan - To assess surrounding tissues and rule out complications
• Magnetic resonance imaging (MRI) - Especially useful for soft-tissue detail and assessing pelvic involvement³

Role of antibiotics in treatment

Acute pouchitis can be easily treated using antibiotics as a form of empirical treatment to control inflammation and infection. Common antibiotics used for acute pouchitis are Ciprofloxacin and Metronidazole. 

Ciprofloxacin in pouchitis treatment

Ciprofloxacin is a bactericidal antibiotic belonging to the fluoroquinolone class. It works by inhibiting bacterial DNA replication through the inhibition of key enzymes, and is a treatment particularly effective against gram-negative bacteria.⁵^,⁶ 

Ciprofloxacin is a useful treatment option in pouchitis as it is considered a cost-effective treatment compared to other treatments in clinical environments.⁵ Additionally, it is effective against both anaerobic and aerobic bacteria, allowing it to target pathogens commonly implicated in pouchitis, such as E. coli and C. perfringens.⁴ 

Ciprofloxacin has demonstrated its effectiveness in clinical trials by successfully reducing PDAI scores from 10.1 to 3.3.⁷ The typical dose for acute pouchitis is 500 mg twice a day for 2-4 weeks.¹

Side effects and risks

Some potential side effects reported in several studies include:

• Nausea 
• Diarrhoea¹
• Vomiting
• Metallic taste 
• Temporary damage to nerves⁸

More serious adverse effects may also occur, such as hyper-/hypoglycemia and photosensitivity to sunlight.⁵

Metronidazole in pouchitis treatment

Metronidazole is a nitroimidazole antibiotic used to treat acute pouchitis, with activity primarily against anaerobic bacteria (no oxygen environments), such as C.perfringens.⁹ It functions by entering the bacteria and becoming activated, leading to DNA damage and celldeath.¹⁰ 

Metronidazole has demonstrated its effectiveness in clinical trials, showing a reduction in PDAI scores from 9.7 to 5.8.⁷ The typical dose for acute pouchitis is 500 mg three times a day for 2-4 weeks.

Side effects and risks

Reported side effects of metronidazole include: 

• Confusion 
• Peripheral neuropathy
• Metallic taste
• Nausea 
• Vomiting 
• Diarrhoea¹⁰

It is recommended to avoid alcohol during Metronidazole treatment and for at least 48 hours after the final dose, as alcohol consumption may trigger adverse reactions such as nausea and vomiting.¹⁰

Long-term or high-dose use increases the risk of more serious complications, including severe neurological effects. 

Comparing ciprofloxacin and metronidazole - monotherapy vs combination therapy

Trials have been carried out to compare the efficacy of Ciprofloxacin and Metronidazole as monotherapies, as well as in combination therapy, for treating pouchitis.⁴ Metronidazole has demonstrated effectiveness against anaerobic bacteria such as C.perfringens, but has limited activity against aerobic bacteria like E. coli. In contrast, Ciprofloxacin has demonstrated to be effective against both aerobic and some anaerobic pathogens, showing broader coverage.¹¹

Additionally, Ciprofloxacin was associated with a greater reduction in PDAI score (by 6.9 points), with fewer adverse effects, in comparison to metronidazole, which reduced the PDAI score by 2.4. Both drugs were effective in treating acute pouchitis but ciprofloxacin had greater efficacy and was better tolerated.¹

Although combination therapy has been explored, trials have found no significant benefit over monotherapy with Ciprofloxacin or Metronidazole alone.¹²

Challenges and considerations

Chronic antibiotic-resistant pouchitis (CARP)

Initial treatment of pouchitis with Ciprofloxacin and Metronidazole typically involves 2-4 weeks. If this standard therapy is not effective, then an extended therapy or a switch to another antibiotic or combination therapy may be recommended. 

However, if symptoms continue after 4 weeks without improvement, the condition is classified as chronic antibiotic-resistant pouchitis (CARP). At this stage, further diagnostic testing is required to select alternative treatments.¹

Chronic antibiotic-dependent pouchitis (CADP)

Approximately 60 % of patients experience recurrent pouchitis, and up to 20% develop chronic forms lasting more than 4 weeks.¹ Returning cases of pouchitis that can be treated effectively using antibiotics but then return soon after antibiotic treatment is stopped are known as chronic antibiotic-dependent pouchitis (CADP). Treatment of CADP requires reinitiation of antibiotic treatment or continuous long-term antibiotic maintenance treatment. Additionally, antibiotic alternative therapies may also be considered.¹³ CADP is typically defined as three or more recurrences of pouchitis following antibiotic therapy.³

Summary

Pouchitis is a common postoperative complication in patients who undergo IPAA surgery. First-line treatments include the drugs ciprofloxacin and metronidazole, which have proven effective in targeting infection and eradicating pathogenic bacteria. However, prolonged or recurrent cases may develop into CARP or CADP. While CADP can easily be treated using longer antibiotic treatment, the management of CARP still poses a major hurdle in healthcare, as it is one of the most common causes of pouch failure.¹⁴ Unlike CADP, CARP requires antibiotic alternative treatments such as faecal microbiota transplant (FMT), immunomodulators, steroids or biologic drugs (monoclonal antibodies).¹

Timely diagnosis, proper classification, and individualised treatment strategies are essential to improve patient outcomes and prevent complications associated with long-term antibiotic use.